Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epinephrine + dexamethasone is a combination therapy consisting of two active pharmaceutical ingredients: - Epinephrine, a sympathomimetic catecholamine that acts primarily as an agonist at alpha and beta adrenergic receptors, leading to bronchodilation, vasoconstriction, increased cardiac output, and reduced mucosal edema. - Dexamethasone, a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. It reduces inflammation by modulating gene expression through the glucocorticoid receptor. This combination has been studied primarily for the treatment of moderate-to-severe bronchiolitis in infants and children. Clinical trials have evaluated its efficacy in reducing hospital admissions compared to monotherapy or placebo. The rationale for combining these agents is that epinephrine provides rapid symptomatic relief via airway smooth muscle relaxation and decreased mucosal swelling, while dexamethasone addresses underlying airway inflammation[2][5][7]. Some studies suggest potential synergistic effects in acute respiratory conditions such as bronchiolitis[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epinephrine + dexamethasone.